An interventional study of watch an instructional video in Medication Compliance, Contraception and Self-Evaluation, sponsored by Tufts Medical Center. Active, not recruiting at 1 site in United States. Open to female participants aged Up to 19 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-06.
Sponsored by Tufts Medical Center · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 463 studies in Medication Adherence with a site in United States — 59 open to participants now, 74 under way, 1 of them phase 3. Medication Adherence · United States.
Among the 463 studies in Medication Adherence with a site in United States, this one is the 340th largest by planned enrollment of the 422 interventional ones that give a count, is one of 26 that started in 2021, is one of 368 with no phase, reaches primary completion later than 16 of the 73 other live ones, and was the 345th registered.
943 studies on the registry are indexed under Medication Adherence; 162 are open to participants now.
Browse Medication Adherence studies →59 of the 463 studies in Medication Adherence with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 15–24
Children's Hospital Los Angeles · Sites in United States
Ages 10–17
Northwestern University · Sites in United States
Ages 60+
University of Oklahoma · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 81 Medication Adherence studies recruiting now, 52 (64%) set no upper age limit and 21 (26%) stop at 75 or younger; 15 take children under 18; 12 take healthy volunteers.
This study: Up to 19 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
463 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 16 · Phase 3 12 · Phase 4 13
First in 1993; this study’s year is marked. 26 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 120 across 773 interventional studies indexed under Medication Adherence.
Median enrollment 96 across the 422 interventional studies, 140 across the 41 observational. Of the 359 that completed or were terminated, 138 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 463 have an industry lead sponsor. The 10 most frequent:
Tufts Medical Center is the lead sponsor of 200 studies on the registry; 27 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 16 (48%) have results posted.
Tufts Medical Center has 2 studies filed under Medication Adherence — fewer than ten, so there is no comparison to draw.
39 of the studies in Medication Adherence with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06550804Phase 3University of Illinois at ChicagoTesting a Real-time Electronic Antiretroviral Adherence Monitoring Intervention | 2027-03 |
| NCT05997914University of Massachusetts, WorcesterStorytelling for Reducing Gap in Anticoagulation Use in African Americans With Atrial Fibrillation | 2026-11 |
| NCT04997499Tufts Medical CenterAdolescent Subcutaneous (SQ) Injection Video Validation | 2026-12 |
| NCT06865755San Diego State UniversityCollaborative Research: Multiscale Modeling and Intervention for Improving Long-Term Medication | 2026-12 |
| NCT07943663nucleusRx IncDevelopment of a Virtual Health Care Platform in Heart Failure Patients Transitioning From Hospital to Home | 2026-12-10 |
Add all 39 to your calendar (.ics) → With an account.
Among the 463 studies in Medication Adherence with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study to determine if a video that utilizes a peer to teach self administration of subcutaneous depot medroxyprogesterone is both effective and well accepted by adolescent patients who are already receiving ongoing treatment with depot medroxyprogesterone by a medical provider via an inter muscular injection. Self administration can be done at home and therefore offers an alternative to traveling to a medical office.
Means of providing health education are rapidly evolving. Telemedicine has become an important modality to provide healthcare and improve access, and will likely be increasingly utilized beyond the COVID-19 pandemic. Telemedicine can effectively provide care and counseling to all age groups, including adolescents. Studies have demonstrated that over 80 percent of adolescents between the ages of 11 and 18 spend one to four hours a day online; searches for health-related information are common. Nevertheless, adolescents may face obstacles when previously familiar aspects of their medical care are abruptly moved online, particularly when discussing contraception. Although traditionally administered in the clinical space, injectable contraception has been shown to be attractive, effective, and well-tolerated by adolescents when subcutaneously self-administered, and can lead to improved continuation rates. The investigators have found that remotely teaching a patient how to self-administer a subcutaneous injection is challenging. The provider may be in a home office, and may not have access to the actual medication or the supplies to demonstrate technique. The patient may struggle to understand verbal instruction without a visual demonstration, resulting in ineffective medication administration. Instructional videos currently available online are not specific to adolescents who use self-administered injectable contraception. Peer education can be relatable and effective for adolescent patients. The investigators propose that self-administration of subcutaneous injectable contraception may be taught using a peer-to-peer video as a synchronous or asynchronous adjunct to consultation with the healthcare professional. Adolescents may be instructed to watch the video demonstration to help inform them about proper technique and ensure safe administration of their medication while at home. This study aims to validate an existing video as an effective teaching tool by assessing metrics such as clarity of the instructions, rate of error, and satisfaction with the video teaching method to the investigators' target population. The video was filmed in accordance with Tufts Medical Center Department of Marketing and Communications policies and the adolescent participant in the video was appropriately consented by a parent/guardian. The video was presented as an oral abstract at the North American Society for Pediatric and Adolescent Gynecology Annual Meeting in March 2021.
Procedure:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This is a single arm interventional study wherein the subjects enrolled will all participate in the study in the same way by watching the teaching video and then will be asked to self inject subcutaneous depot-medroxyprogesterone as per the protocol. All participants will then be asked to answer survey questions. All health care providers that participate in the study will likewise be asked to answer survey questions.
Behavioral: watch an instructional video
watch instructional video and then perform self injection of subcutaneous depot-medroxyprogesterone based on the video teaching
Supervised self-injection
This measure is coded 1 if the patient successfully completes self-injection at the first session after watching the video. Otherwise, the measure is coded 0. Incomplete attempts, such preparing for but not completing the injection, will be coded 0.
Time frame: 12-18 months
Sustained self-injection
This measure will be a count of self reported self injections in the 10-14 weeks following initial visit. This information will be collected through a self reported electronic REDCap survey that is administered once after the initial survey.
Time frame: 12-18 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Sep 2021 (actual). Primary completion is estimated for Dec 2026, 63 months after the start.
Of 429 non-industry interventional studies with no phase under Medication Adherence, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 42. This study's planned 63 months is above that.
Counting every sponsor, half of 447 studies reached it within 22 months; a quarter within 11 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.